Skip to content

Can I take vitamin K2 with Eliquis (apixaban)?

Short answer: The Eliquis label names vitamin K only where it discusses reversing apixaban during bleeding and never discusses K2 supplements; NIH's vitamin K warning names warfarin and similar vitamin K antagonist blood thinners, not apixaban.

Vitamin K is on the Eliquis label, but only where it discusses reversing apixaban during bleeding: "Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of apixaban." The label does not mention vitamin K supplements or K2, and we found no study of K2 taken with apixaban. NIH's vitamin K warning names warfarin, a blood thinner that works differently, not apixaban.

How well documented: On the drug’s label. The medicine’s FDA-approved label names this supplement, or the kind of product it is.

What's known

  • On the label. In its section on reversing apixaban's effect during bleeding, the Eliquis label says: "Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of apixaban." The label does not mention vitamin K supplements, K2 or menaquinone. (Eliquis label)
  • Don't stop it on your own. The label's boxed warning says: "Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events." (Eliquis label)
  • NIH names warfarin. NIH's vitamin K fact sheet says: "Vitamin K can have a serious interaction with the blood thinner warfarin (Coumadin)." Neither NIH vitamin K fact sheet mentions apixaban. (NIH ODS; NIH ODS professional)
  • No study of the pair. We found no study or case report of vitamin K2 taken with apixaban. A 2021 review of food and supplement interactions with apixaban and similar drugs says: "DOACs were initially considered drugs with no significant food interactions; however, clinical observations from daily practice have proved otherwise as interactions with food ingredients have been reported." Its summary names St John's wort and no vitamin K supplement: "Patients treated with anticoagulants should avoid products containing St. John's wort and take special care with other food ingredients." (Grześk 2021)
  • St John's wort on the label. The Eliquis label says: "Avoid concomitant use of ELIQUIS with combined P-gp and strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) because such drugs will decrease exposure to apixaban [see Clinical Pharmacology (12.3)]." (Eliquis label, 7.2)

What to do

  • NIH's Office of Dietary Supplements (ODS) says: Vitamin K can have a serious interaction with the blood thinner warfarin (Coumadin). If you take warfarin, make sure that the amount of vitamin K you consume from food and supplements is about the same every day. A sudden change in the amount of vitamin K you get can cause dangerous bleeding (if you consume less) or blood clots (if you consume more). Tell your doctor, pharmacist, and other health care providers about any dietary supplements and prescription or over-the-counter medicines you take. Don't give vitamin K supplements to a child unless their doctor advises it.
  • St John's wort and medicines: in 12 healthy women taking an ethinyl estradiol-norethindrone pill, bleeding between periods occurred in 2 of 12 without the herb and in 7 of 12 while taking it, and the authors advise expecting this and adding a barrier method; a systematic review found more such bleeding in three studies and follicle growth with probable ovulation in one ('limited evidence'), and unwanted pregnancies on the pill with St John's wort are a well-documented interaction. It can cause serotonin syndrome with SSRIs or other serotonin reuptake inhibitor antidepressants, or with buspirone; the review names sertraline, paroxetine and nefazodone among those antidepressants, and serotonin syndrome or lethargy has been reported with serotonin reuptake inhibitors. Reviews describe relevant and in some cases life-threatening interactions with other medicines: it lowers blood levels of cyclosporine and of antiretroviral drugs (such as indinavir and nevirapine) and anticancer drugs (irinotecan, imatinib), and lowers the level or effect of alprazolam, amitriptyline, digoxin, fexofenadine, methadone, simvastatin, tacrolimus, theophylline, warfarin, phenprocoumon and oral contraceptives. Patients treated with anticoagulants should avoid products containing St John's wort.
  • NIH's National Center for Complementary and Integrative Health (NCCIH) says: 'It has been clearly shown that St. John’s wort can interact in dangerous, sometimes life-threatening ways with a variety of medicines.' 'If taken orally in large doses or applied to the skin, St. John’s wort might cause severe skin reactions after sun exposure. Other side effects can include diarrhea, dizziness, trouble sleeping, restlessness, and skin tingling. If you take any type of medicine, talk with your health care provider before using St. John’s wort or other herbal products; some herbs and medicines interact in harmful ways. For example, St. John’s wort can weaken the effects of many medicines, including crucially important medicines such as: some antidepressants, including amitriptyline and bupropion; birth control pills; cyclosporine, which prevents the body from rejecting transplanted organs; some drugs used to prevent seizures, including phenytoin and carbamazepine; some heart medications, including digoxin and ivabradine; some HIV drugs, including indinavir and nevirapine; some cancer medications, including irinotecan, imatinib, and docetaxel; warfarin, an anticoagulant (blood thinner); certain statins, including simvastatin. In addition, taking St. John’s wort with certain antidepressants or other drugs that affect serotonin (a substance produced by some nerve cells) may lead to increased serotonin-related side effects, which can be serious. It may be unsafe to use St. John’s wort during pregnancy because it may increase the risk of birth defects. Breastfeeding infants of mothers who take St. John’s wort can experience colic, drowsiness, and lethargy.' 'Depression can be a serious illness. If you or someone in your family may have depression, consult a health care provider.' 'Although it is important to tell your health care providers about any complementary health approaches you use, this is especially crucial for St. John’s wort because this herb interacts with so many medicines. Interactions with St. John’s wort can weaken the effects of life-saving medicines or cause dangerous side effects.' Health Canada's monograph on St. John's wort (oral) says, for products for healthy mood balance: 'Ask a health care practitioner [doctor] before use if you have a psychological disorder such as anxiety or depression.' For all products: 'Ask a health care practitioner [doctor] before use if you are pregnant or breastfeeding. Ask a health care practitioner [doctor] before use if you are taking seizure medications, antihistamines, bronchodilators, muscle relaxants and/or opiates. When using this product avoid prolonged exposure to sunlight, ultraviolet light (UV) or UV therapy. When using this product exercise caution if you drive or use machinery as you may experience drowsiness. Ask a health care practitioner [doctor] if symptoms persist or worsen.' As a contraindication: 'Do not use if you are taking antidepressants, anxiolytics, anti-cancer, cardiovascular, contraceptive medications, blood thinners, anti-HIV agents and/or medications to suppress the immune system.' As known adverse reactions: 'When using this product you may experience mild gastrointestinal disturbances, restlessness, and/or headaches. Stop use and ask a health care practitioner [doctor] if you experience muscle rigidity or contractions, tremors, agitation/confusion, increased heart rate, or hypersensitivity/allergy.' Memorial Sloan Kettering says: 'Side effects of using St. John’s wort may include: headache, nausea (feeling like you’re going to throw up), dry mouth, abdominal (belly) discomfort, sleepiness, increased sensitivity to sunlight. Talk with your healthcare provider if you are: Taking a blood thinner, such as warfarin (Coumadin®, Jantoven®). St. John’s wort can affect the way it works. Taking a cholesterol-lowering medication, such as simvastatin (FloLipid®, Zocor®). St. John’s wort can make it less effective. Taking a heart medication, such as digoxin (Digox®, Lanoxin®). St. John’s wort makes it less effective. Taking antidepressants, such as fluoxetine (Prozac®) or paroxetine (Paxil®). St. John’s wort can make them less effective. Taking a birth control pill. St. John’s wort can affect the way the pill works in your body. An organ transplant patient and are taking cyclosporine (Sandimmune®, Neoral®) or tacrolimus (Prograf®). St. John’s wort can make these medications less effective. This can make your body reject the transplant. Taking the chemotherapy medications irinotecan (Onivyde®, Camptosar®) or imatinib (Gleevec®). St. John’s wort can make these less effective. Taking indinavir (Crixivan®) to treat HIV (human immunodeficiency virus) infection. St. John’s wort makes it less effective by reducing its level in your blood. Don’t take St. John’s wort if you’re pregnant or breastfeeding. It may not be safe for you.' For health professionals it lists contraindications: 'Pregnant or nursing women or those on oral contraceptives should not consume St. John's wort. Patients being treated with prescription antidepressants should not consume St. John's wort as it may create a syndrome of central serotonin excess. Use of this supplement should also be avoided if taking other supplements such as 5-HTP or SAM-e because these products may also affect serotonin levels. Numerous documented interactions with conventional drugs should preclude its use while undergoing chemotherapy, radiation therapy, antiretroviral therapy, immunosuppressive therapy, and anticoagulant therapy.'; adverse reactions: 'Common: Headache, nausea, dry mouth, sleepiness, and gastrointestinal upset. Infrequent: Photosensitivity, neuropathy, increased prothrombin time. Acute transplant rejection: In 2 heart transplant patients maintained on immunosuppressives, directly linked to the use of St. John’s wort. After supplement discontinuation, plasma cyclosporin returned to therapeutic values. A subsequent report of 45 kidney or liver transplant recipients also describe rejection episodes or declines in trough levels of cyclosporin (average, 49%) linked to ingestion of St. John’s wort. In many cases, these patients did not inform their healthcare team about their use of this supplement. Acute kidney injury: In a patient who used St. John’s wort tea to remedy a sleep disorder. Supraventricular tachycardia: In a 33-year-old female, 1 month after using St. John's wort for depression as recommended by a psychotherapist. Cardiovascular collapse: Hypotension without anaphylactic symptoms shortly after anesthesia induction was potentially linked to long-term use of St. John’s wort in a patient. Severe drug-induced acute hepatitis: In a 61-year-old woman, linked to use of St. John's wort during treatment with pegylated interferon α. Mania: In 3 patients with underlying bipolar disorder associated with use of St. John's wort. Serotonin syndrome: In a patient following 10 days of St. John’s wort use. In a case series, 5 elderly patients who combined prescription antidepressants with St. John's wort were clinically diagnosed with central serotonergic syndrome. Erythroderma: In a patient 4 days after initiation of St. John’s wort, affecting both light- and non-exposed skin. Severe skin toxicity: In a 63-year-old cancer patient undergoing radiation/multimodal treatment while using several other over-the-counter products including topical St. John's wort skin oil. Radiation recall dermatitis: In a 65-year-old cancer patient who developed unusual skin reactions during RT and erythema half a year later in previously irradiated skin, associated with use of hypericin for depressive mood without informing the physician. Photosensitivity: In 3 individuals who used topical and/or oral St. John's wort preparations prior to sun exposure or undergoing phototherapy. Subacute toxic neuropathy: In a 35-year-old woman who took St. John’s Wort for mild depression. Stinging pain on sun-exposed areas developed after 4 weeks of use which worsened during and after sun exposure. Pain was also provoked by light touch or air movement. Sexual dysfunction: Decreased sexual libido that normalized following discontinuation of St. John's wort. Withdrawal syndrome: Nausea, anorexia, retching, dizziness, dry mouth, thirst, chills, and extreme fatigue in a patient who stopped taking St. John’s wort after 32 days of use. Psychosis: Regular ingestion of a St. John’s wort tea was noted as a potential contributing factor in a 25-year-old man who also had a history of drug-induced psychosis and family history of psychotic depression.'; herb-drug interactions: 'CYP450 substrate drugs including those metabolized by 3A4 and 2C9: St. John's wort induces these isoenzymes, affecting the metabolism of certain medications and reducing serum concentrations. Drugs metabolized by these enzymes include: HIV protease inhibitors: Blood levels of indinavir and ritonavir can be significantly reduced, resulting in increased HIV viral load and development of viral resistance. HIV non-nucleoside reverse transcriptase inhibitors: Increased oral clearance and lowered plasma concentrations of nevirapine possibly resulting in antiretroviral resistance and treatment failure. Cyclosporin / tacrolimus: Blood levels of cyclosporin or tacrolimus can be significantly reduced, resulting in decreased efficacy or acute transplant rejection. Diltiazem / nifedipine: Blood levels of diltiazem or nifedipine can be reduced, resulting in decreased efficacy. Irinotecan: Due to changes in hepatic metabolism caused by St. John's wort, levels of irinotecan metabolite SN-38 may be lowered by as much as 40% for up to 3 weeks following discontinuation of St. John's wort. Imatinib: Increased clearance. Docetaxel: Subtherapeutic docetaxel concentrations may result when docetaxel is administered to patients who regularly use St. John's wort. Warfarin: May increase or decrease activity when administered concomitantly. Internal normalization ratio should be monitored routinely. Clopidogrel: May enhance clopidogrel-induced platelet inhibition. Triptans: Increased serotonergic effect and possible serotonin syndrome when combined with sumatriptan, naratriptan, rizatriptan, or zolmitriptan. SSRIs: Increased serotonergic effect and possible serotonin syndrome when combined with citalopram, fluoxetine, fluvoxamine, paroxetine, or sertraline. Tricyclic antidepressants: Increased serotonergic effect and possible serotonin syndrome when combined with nefazodone, amitriptyline, or imipramine. Possible reduction in efficacy of antidepressants due to changes in metabolism. Zolpidem: Decreased plasma concentration. Oral contraceptives: May reduce blood levels resulting in decreased efficacy (ie, breakthrough bleeding or pregnancy). Alcohol: May result in increased sedation. Alprazolam: May reduce blood levels, resulting in decreased efficacy. Dextromethorphan: May reduce blood levels, resulting in decreased efficacy. Statins: Increased clearance and reduced efficacy of simvastatin, atorvastatin, and rosuvastatin. Oxycodone: Reduces oxycodone plasma concentrations, significantly reducing its effectiveness. Gliclazide: Increased clearance. Clozapine: Reduces plasma level of clozapine. Methotrexate: Increases exposure and toxicity of methotrexate in rats. Bupropion: Prolonged facial dystonia in a 58-year-old Caucasian woman following concomitant use of St. John's wort. Rifampicin: Allodynia, paresthesia, and phototoxic erythrodermia in sun-exposed areas (back of the hands and perioral and nasal area) of female volunteers following coadministration with St. John’s wort. Ambrisentan: St. John's wort significantly reduced exposure with ambrisentan, but this interaction was deemed not to be clinically relevant. Intravenous fentanyl: In a small study ofhealthy volunteers, St. John's wort did not alter fentanyl PK/PD or clinical effects. P-gp substrate drugs: St. John's wort induces intestinal P-gp, resulting in decreased absorption and lowered plasma concentrations of certain drugs including digoxin, talinolol, and fexofenadine. It may also produce severe adverse effects in conjunction with pegylated interferon α. UGT substrates: St. John's wort modulates UGT enzymes in vitro and may increase the side effects of drugs such as acetaminophen. Dolutegravir: Concomitant administration of a hypericum-containing supplement in an HIV-infected patient had no significant effects on plasma drug trough concentrations of this drug. Use of therapeutic drug monitoring and/or viral load is recommended to assess any potential effects with prescribed co-administration.'.
  • The Eliquis Medication Guide says: "Tell your healthcare provider about all the medicines you or your child take, including prescription and over-the-counter medicines, vitamins, and herbal supplements." (Eliquis label)
  • Don't stop or change a prescribed medicine on your own.

Sources

  1. US National Library of Medicine. Eliquis (apixaban) tablets: prescribing information and Medication Guide. DailyMed, revised August 2026. DailyMed
  2. National Institutes of Health, Office of Dietary Supplements. Vitamin K: Fact Sheet for Consumers. NIH ODS
  3. National Institutes of Health, Office of Dietary Supplements. Vitamin K: Fact Sheet for Health Professionals. NIH ODS
  4. Grześk G, et al. The Clinical Significance of Drug-Food Interactions of Direct Oral Anticoagulants. Int J Mol Sci. 2021. PubMed 34445237 · doi:10.3390/ijms22168531